Dr. Reddy’s Laboratories, Inc. (NYSE: RDY) is an India-based global pharmaceutical company founded in 1984 by Dr. Kallam Anji Reddy. Headquartered in Hyderabad, it has grown from a regional active pharmaceutical ingredient (API) supplier into a fully integrated organization with research-driven capabilities spanning generic drugs, proprietary products and biosimilars. Over nearly four decades, the company has established a network of manufacturing sites and R&D centers across Asia, Europe and North America, positioning itself as a diversified player in the global pharmaceutical industry.
The company’s core business is divided into three main segments. In its Generics division, Dr. Reddy’s offers a broad portfolio of affordable medicines across therapeutic areas such as cardiovascular, gastrointestinal, oncology and pain management. Its Active Pharmaceutical Ingredients segment supports internal needs and external customers with high-quality intermediates and APIs. Meanwhile, the Proprietary Products and Biosimilars segment focuses on innovative therapies, including specialty drugs and complex biologics, with ongoing development programs in oncology, autoimmune disorders and metabolic diseases.
Dr. Reddy’s maintains a strong geographic presence in the United States, Europe, India and key emerging markets in Russia, Latin America and Asia Pacific. The company’s U.S. operations are anchored by a generics business that leverages filing and manufacturing expertise to bring abbreviated new drug applications (ANDA) to market. In Europe, it operates through subsidiaries and partnerships to distribute both generics and specialty products, while its India operations serve a fast-growing domestic market. Research collaborations and strategic alliances underpin its efforts to expand biosimilar franchises globally.
Leadership at Dr. Reddy’s reflects its commitment to innovation and quality. The board is chaired by Mr. Kallam Satish Reddy, son of the founder, who oversees corporate strategy and global expansion. The management team includes experienced executives in R&D, manufacturing and commercial operations, with senior research facilities in Hyderabad, Europe and the U.S. Under this leadership, Dr. Reddy’s continues to invest in advanced drug delivery technologies, biosimilar development platforms and digital initiatives aimed at improving patient access and outcomes.
